Enzon Pharmaceuticals Company Profile (NASDAQ:ENZN)

About Enzon Pharmaceuticals (NASDAQ:ENZN)

Enzon Pharmaceuticals logoEnzon Pharmaceuticals, Inc. receives royalty revenues from existing licensing arrangements with other companies primarily related to sales of four marketed drug products: PegIntron, Sylatron, Macugen and CIMZIA. The Company has no clinical operations and limited corporate operations. PegIntron is used both as a monotherapy and in combination with REBETOL (ribavirin) capsules for the treatment of chronic hepatitis C. Macugen is used for the treatment of neovascular (wet) age-related macular degeneration. Sylatron is used for the treatment of melanoma. CIMZIA is used for the treatment of moderate to severe rheumatoid arthritis and Crohn's disease. CIMZIA is a biologic medicine that counteracts tumor necrosis factor (or TNF), which promotes inflammation of the joints in rheumatoid arthritis.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:ENZN
  • CUSIP: 29390410
  • Web: enzon.com/
Capitalization:
  • Market Cap: $16.4 million
  • Outstanding Shares: 44,214,000
Average Prices:
  • 50 Day Moving Avg: $0.32
  • 200 Day Moving Avg: $0.30
  • 52 Week Range: $0.22 - $0.50
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.000
Sales & Book Value:
  • Annual Revenue: $6.53 million
  • Price / Sales: 2.51
  • Book Value: $0.25 per share
  • Price / Book: 1.50
Profitability:
  • Net Margins: 44.79%
  • Return on Equity: 24.28%
  • Return on Assets: 22.93%
Misc:
  • Average Volume: 90,989 shs.
  • Short Ratio: 1.03
 
Frequently Asked Questions for Enzon Pharmaceuticals (NASDAQ:ENZN)

What is Enzon Pharmaceuticals' stock symbol?

Enzon Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENZN."

How were Enzon Pharmaceuticals' earnings last quarter?

Enzon Pharmaceuticals Inc (NASDAQ:ENZN) released its earnings results on Wednesday, August, 10th. The company reported $0.02 earnings per share for the quarter. The firm had revenue of $2.27 million for the quarter. Enzon Pharmaceuticals had a return on equity of 24.28% and a net margin of 44.79%. View Enzon Pharmaceuticals' Earnings History.

Who are some of Enzon Pharmaceuticals' key competitors?

Who are Enzon Pharmaceuticals' key executives?

Enzon Pharmaceuticals' management team includes the folowing people:

  • Jonathan N. Christodoro, Chairman of the Board
  • Andrew D. Rackear J.D., Chief Executive Officer, Secretary
  • Richard L. Feinstein, Chief Financial Officer, Vice President - Finance
  • Odysseas D. Kostas M.D., Director
  • Jennifer I. McNealey, Director

Who owns Enzon Pharmaceuticals stock?

Enzon Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include COUCHMAN JONATHAN (5.50%). View Institutional Ownership Trends for Enzon Pharmaceuticals.

How do I buy Enzon Pharmaceuticals stock?

Shares of Enzon Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Enzon Pharmaceuticals' stock price today?

One share of Enzon Pharmaceuticals stock can currently be purchased for approximately $0.37.


MarketBeat Community Rating for Enzon Pharmaceuticals (NASDAQ ENZN)
Community Ranking:  1.9 out of 5 ()
Outperform Votes:  5 (Vote Outperform)
Underperform Votes:  8 (Vote Underperform)
Total Votes:  13
MarketBeat's community ratings are surveys of what our community members think about Enzon Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Enzon Pharmaceuticals (NASDAQ:ENZN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Enzon Pharmaceuticals (NASDAQ:ENZN)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Enzon Pharmaceuticals (NASDAQ:ENZN)
Earnings by Quarter for Enzon Pharmaceuticals (NASDAQ:ENZN)
Earnings History by Quarter for Enzon Pharmaceuticals (NASDAQ ENZN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/10/2016Q3 2016$0.02$2.27 millionViewN/AView Earnings Details
3/18/2013Q4 2012($0.11)$10.01 million$10.65 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Enzon Pharmaceuticals (NASDAQ:ENZN)
Current Year EPS Consensus Estimate: $0.030 EPS

Dividends

Dividend History by Quarter for Enzon Pharmaceuticals (NASDAQ ENZN)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
12/7/2015special$0.2512/30/201512/14/201512/29/2015
7/7/2015special$0.508/13/20157/21/20158/12/2015
12/9/2014special$0.101/8/20151/12/20151/28/2015
12/9/2013special$0.4512/24/201312/16/201312/23/2013
4/23/2013special$1.605/3/20135/7/20136/4/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Enzon Pharmaceuticals (NASDAQ:ENZN)
Insider Trades by Quarter for Enzon Pharmaceuticals (NASDAQ:ENZN)
Insider Trades by Quarter for Enzon Pharmaceuticals (NASDAQ:ENZN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/28/2016Carl C IcahnMajor ShareholderBuy694,023$0.41$284,549.43View SEC Filing  
9/19/2013Robert LebuhnDirectorSell55,926$1.72$96,192.72View SEC Filing  
8/10/2012Robert LebuhnDirectorSell1,933$6.58$12,719.14View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Enzon Pharmaceuticals (NASDAQ:ENZN)
Latest Headlines for Enzon Pharmaceuticals (NASDAQ:ENZN)
Source:

Social

Chart

Enzon Pharmaceuticals (ENZN) Chart for Wednesday, July, 26, 2017

This page was last updated on 7/26/2017 by MarketBeat.com Staff